Cargando…

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

Improvements in screening and adjuvant therapy for breast cancer are associated with decreased recurrence, which may have the effect of increasing the proportion of patients presenting with first-line de novo versus recurrent metastatic breast cancer (MBC). Here, we describe and compare patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yardley, Denise A., Kaufman, Peter A., Brufsky, Adam, Yood, Marianne Ulcickas, Rugo, Hope, Mayer, Musa, Quah, Cheng, Yoo, Bongin, Tripathy, Debu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031392/ https://www.ncbi.nlm.nih.gov/pubmed/24706168 http://dx.doi.org/10.1007/s10549-014-2916-8

Ejemplares similares

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
por: Tripathy, Debu, et al.
Publicado: (2014)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
por: Kaufman, Peter A, et al.
Publicado: (2014)

Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
por: Malmgren, Judith A., et al.
Publicado: (2017)

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study
por: Haque, Reina, et al.
Publicado: (2017)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer
por: Barcenas, Carlos H., et al.
Publicado: (2021)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
por: Chien, A. Jo, et al.
Publicado: (2012)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes
por: Robert, Nicholas J., et al.
Publicado: (2017)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
por: Miller, Kathy, et al.
Publicado: (2016)

Sustained Hyperglycemia Among Patients With Diabetes: What matters when action is needed?
por: Lafata, Jennifer E., et al.
Publicado: (2009)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study
por: Zhang, Yang, et al.
Publicado: (2023)

Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score
por: Ebner, Florian, et al.
Publicado: (2023)

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2020)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study
por: Kubo, Makoto, et al.
Publicado: (2019)

The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
por: Rugo, Hope S., et al.
Publicado: (2019)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Potential misinterpretations caused by collapsing upper categories of comorbidity indices: An illustration from a cohort of older breast cancer survivors
por: Ahern, Thomas P, et al.
Publicado: (2009)

Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries
por: Persson, Rebecca, et al.
Publicado: (2019)

Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011
por: Malmgren, Judith, et al.
Publicado: (2018)

Role of hormonal risk factors in HER2-positive breast carcinomas
por: Balsari, A, et al.
Publicado: (2003)

2435: Accuracies of using Her2 for prognosis of breast cancer recurrence in Life After Cancer Epidemiology (LACE) Study
por: Nan Hu,
Publicado: (2018)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_952l3ah30gsdstqudc82v79b7i